Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OmaliRel
- Development stage
- Unknown
- Lead developer
- Reliance Life Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
OmaliRel is a humanized IgG1κ monoclonal antibody developed and manufactured by Reliance Life Sciences as a biosimilar to the reference product omalizumab. It functions by selectively binding to human immunoglobulin E (IgE), specifically targeting the FcεR1 epitope. This binding prevents free circulating IgE from interacting with high-affinity IgE receptors (FcεRI) on the surface of mast cells and basophils, thereby inhibiting the release of inflammatory mediators like histamine that drive the allergic cascade. Administered via subcutaneous injection, OmaliRel is approved in India for the treatment of moderate-to-severe allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps.
- Brand names
- OmaliRel
- Other names
- omalizumab
02
Targets
IgE-CH3 (Immunoglobulin heavy constant epsilon Cε3 domain)
Beyond the preview
Go deeper on OmaliRel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmaliRel.